For the first time, a research team from China used a new technique to fix a blood disorder in human embryos. The scientists performed "chemical surgery" -- a procedure that rewrites errors in genetic code instead of snapping and replacing strands of faulty DNA, which is the central strategy employed by the CRISPR gene editing system. The early results look promising, but this technology is still a long way from prime time.